A Study to Test Whether Different Doses of Alteplase Help People With Severe Breathing Problems Because of COVID-19

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

December 16, 2020

Primary Completion Date

July 19, 2022

Study Completion Date

July 25, 2022

Conditions
Acute Respiratory Distress Syndrome
Interventions
PROCEDURE

Standard of care

Standard of Care (SOC) includes any supportive measures applied in hospital, specifically on an intensive care unit (ICU), such as for example the use of non-invasive or invasive ventilation, oxygen masks, haemodynamic support, if needed, sedation, as well as medical therapies commonly used in patients suffering from acute respiratory distress syndrome (ARDS) or its complications. SOC should include best possible treatment regimen established locally and should be in line with current guidelines for ARDS treatment.

DRUG

Alteplase low dose

0.3 milligram/kilogram (mg/kg) over 2 hours (Day 1) immediately followed by daily infusion of 0.02 mg/kg/hour over 12 hours (starting on Day 1 and up to Day 5). One optional additional infusion of 0.3 mg/kg over 2 hours could be given once on Days 2 to 5 in case of clinical worsening, per investigator judgement.

DRUG

Alteplase high dose

0.6 milligram/kilogram (mg/kg) over 2 hours (Day 1) immediately followed by daily infusion of 0.04 mg/kg/hour over 12 hours (starting on Day 1 and up to Day 5). One optional additional infusion of 0.6 mg/kg over 2 hours could be given once on Days 2 to 5 in case of clinical worsening, per investigator judgement.

Trial Locations (37)

1070

ULB Hopital Erasme, Brussels

1100

Wiener Gesundheitsverbund Klinik Favoriten, Vienna

1340

Ottignies - HOSP St-Pierre, Ottignies

4000

Centre Hospitalier Universitaire de Liège, Liège

9020

LKH Klagenfurt am Woerthersee, Klagenfurt

11009

Hospital Puerta del Mar, Cadiz

20089

Istituto Clinico Humanitas, Rozzano (MI)

20132

IRCCS San Raffaele, Milan

20230

Hospital Cardiologica Aguascalientes, Aguascalientes

30625

Medizinische Hochschule Hannover, Hanover

35110

Izmir Dr. Suat Seren Gogus Hastaliklari ve Cerrahisi Egitim ve Arastirma Hastanesi, Izmir

42283

Petrus-Krankenhaus, Wuppertal

44093

HOP Hôtel-Dieu, Nantes

51092

HOP Robert Debré, Reims

59037

HOP Roger Salengro, Lille

67091

HOP Civil, Strasbourg

68167

Universitätsklinikum Mannheim GmbH, Mannheim

69120

Universitätsklinikum Heidelberg, Heidelberg

75014

HOP Cochin, Paris

75908

HOP Européen G. Pompidou, Paris

77000

HOP Melun-Sénart, Melun

81377

Klinikum der Universität München - Campus Großhadern, München

94275

HOP Bicêtre, Le Kremlin-Bicêtre

98000

Hospital Miri, Miri

108814

City Clinical Hospital # 40 of the Moscow Health Department, Moscow

119048

Moscow 1st State Med.Univ.n.a.I.M.Sechenov, Moscow

187342

"State Budget Institution of Healthcare Leningradskaya region Kirovskaya Interdistrict Hospital", Saint Petersburg

390026

City Clinical Emergency Hospital, Ryazan

530002

King George Hospital, Visakhapatnam

90470-340

Hospital Mae de Deus, Porto Alegre

04109

Universitätsklinikum Leipzig, Leipzig

7334 DZ

Gelre Ziekenhuizen Apeldoorn, Apeldoorn

6815 AD

Rijnstate Hospital, Arnhem

6532 SZ

Canisius-Wilhelmina ziekenhuis, Nijmegen

08003

Hospital del Mar, Barcelona

08035

Hospital Vall d'Hebron, Barcelona

08208

CS Parc Taulí, Sabadell

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT04640194 - A Study to Test Whether Different Doses of Alteplase Help People With Severe Breathing Problems Because of COVID-19 | Biotech Hunter | Biotech Hunter